BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Wednesday, February 11, 2026
See today's BioWorld
Home
» Two Aussie Biotechs Merging to Focus on Phase III HIV Dru
To read the full story,
subscribe
or
sign in
.
Two Aussie Biotechs Merging to Focus on Phase III HIV Dru
Dec. 23, 2008
By
Catherine Hollingsworth
Australian biotech firms Progen Pharmaceuticals Ltd. and Avexa Ltd. have agreed to merge, creating a new company with a well-funded oncology and HIV pipeline. (BioWorld Today)
BioWorld
